MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Geschlossen

BrancheGesundheitswesen

13.23 0.08

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.15

Max

13.36

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.5B

14B

Verkäufe

3.4B

84B

KGV

Branchendurchschnitt

17.587

63.778

EPS

16.936

Dividendenrendite

0.72

Gewinnspanne

16.795

Angestellte

27,048

EBITDA

2.4B

24B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+37.57% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.72%

2.39%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

8.8B

11B

Vorheriger Eröffnungskurs

13.15

Vorheriger Schlusskurs

13.23

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Juni 2024, 13:33 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update

26. Juni 2024, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million

25. Apr. 2024, 10:32 UTC

Ergebnisse

Nestle India Reports Rise in Quarterly Profit, Announces JV With Dr. Reddy's Laboratories

23. Jan. 2025, 17:46 UTC

Ergebnisse

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23. Jan. 2025, 17:42 UTC

Ergebnisse

Dr. Reddy's 3Q Rev INR83.59B

5. Nov. 2024, 11:01 UTC

Ergebnisse

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5. Nov. 2024, 11:00 UTC

Ergebnisse

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5. Nov. 2024, 10:57 UTC

Ergebnisse

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5. Nov. 2024, 10:57 UTC

Ergebnisse

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

26. Juni 2024, 11:54 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon: All Other 2024 Guidance Unchanged

26. Juni 2024, 11:54 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%

26. Juni 2024, 11:52 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon: Sale Allow For NRT Exit Outside US, Trims Business Complexity

26. Juni 2024, 11:51 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon: Deal Expected to Complete Early 4Q

26. Juni 2024, 11:50 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon: Use of Proceeds Will Be in Line With Capital Allocation Priorities

26. Juni 2024, 11:49 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon: Deal Structure Upfront Cash GBP458M, GBP42M Performance-Based Payable

26. Juni 2024, 11:48 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon: Portfolio Includes Nicotinell, Nicabate, Habitrol and Thrive Available in Gum, Lozenge

26. Juni 2024, 11:47 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon: Deal Worth GBP500M With Additional Proceeds From Inventory Transfer

26. Juni 2024, 11:46 UTC

Akquisitionen, Fusionen, Übernahmen

Haleon to Sell Non-US Nicotine Replacement Therapy Business to Dr. Reddy's Laboratories

7. Mai 2024, 10:56 UTC

Ergebnisse

Dr. Reddy's Laboratories 4Q Net INR13.07B Vs. Net INR9.59B >500124.BY

7. Mai 2024, 10:55 UTC

Ergebnisse

Dr. Reddy's Laboratories 4Q Rev INR70.83B Vs. INR62.97B >500124.BY

Peer-Vergleich

Kursveränderung

Dr Reddy's Laboratories Ltd-ADR Prognose

Kursziel

By TipRanks

37.57% Vorteil

12-Monats-Prognose

Durchschnitt 18.2 USD  37.57%

Hoch 19.4 USD

Tief 17 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Dr Reddy's Laboratories Ltd-ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

13.21 / 13.685Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.